drugset / Trial / NCT00223158

Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer

NCT00223158

Completed 70 enrolled Patrice Perron Theramed co. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the hypothyroid state in patients with thyroid cancer prepared either by placebo or L-T3 following L-T4 withdrawal in preparation for whole body scintigraphy. To evaluate the time needed for TSH elevation (\> 30 mUI/L) on placebo vs. L-T3.

Timeline

Start
2003-09
Primary completion
2005-05
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Liothyronine Small molecule 50 mg

Indications